Studies have shown that active fund managers routinely underperform the S&P500 index*​

Outlook Therapeutics, Inc. (NASDAQ: OTLK)

OTLK Stock Predictions and Ratings

WSX Rating:
STRONG SELL
WSX Forecast (1yr):
-20.90%
Analyst Rating:
HOLD
Analyst Forecast (1yr):
100.70%

OTLK Stock Analysis

OTLK PE Ratio:

OTLK PEG Ratio: Not Available

OTLK Forward EPS Growth (12 month): 0.00%

OTLK PS Ratio: 96.7

OTLK PSG Ratio: Not Available

OTLK Forward Revenue Growth (12 month): 0.00%

OTLK Articles

No data was found